Table 2.
Baseline characteristics of HIV infected children in HIV clinic at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia from April 1 to May 15, 2018 (n = 318).Baseline characteristics of
| Variables | N (%) |
|---|---|
| Age years (at the time of cART initiation) | |
| ≤ 11 months | 91(28.6) |
| 12 to 34 months | 63(19.8) |
| 35–59 months | 52(16.4) |
| ≥ 60 months | 112(35.2) |
| Initial HAART Regimen | |
| D4T-3TC-NVP | 59(18.5) |
| D4T-3TC-EFV | 17(5.3) |
| AZT-3TC-NVP | 103(32.3) |
| AZT-3TC-EFV | 53(16.6) |
| TDF-3TC-EFV | 26(8.1) |
| AZT-3TC-LPV/r | 10(3.1) |
| ABC-3TC-LPV/r | 6(1.5) |
| ABC-3TC-EFV | 23(7.2) |
| D4T-3TC-LPV/r | 21(6.6) |
| Initial cART dosing preparations | |
| One loose | 94(29.6) |
| Three loose | 81(25.5) |
| Fixed | 143(45) |
| PMTCT Service | |
| Present | 21(6.6) |
| None | 237(74.5) |
| Unknown | 60(18.8) |
| Infant ART Prophylaxis | |
| Yes | 37(11.6) |
| No | 235(73.8) |
| Unknown | 56(17.6) |
| Baseline Immunosuppression level | |
| Not Significant Immunosuppression (≥ 500 or > 25%) | 3(0.94) |
| Mild Immunosuppression (350–499 or 20–24%) | 23(7.2) |
| Advanced Immunosuppression (200–349 or 15–19%) | 137(43.08) |
| Severe Immunosuppression (< 200 or < 15%) | 155(48.74) |
| Base line WHO staging | |
| Stage 1 | 26(8.17) |
| Stage 2 | 109(34.3) |
| Stage 3 | 155(48.7) |
| Stage 4 | 28(8.8) |